SCHEMBL14740730

SCHEMBL14740730

O=C1C(=O)N(c2ccccn2)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
CES1 P23141 5/20 0.58
NPSR1 Q6W5P4 3/20 0.58
GAA P10253 2/20 0.58
BCHE P06276 2/20 0.58
CES2 O00748 1/20 0.58
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TTR P02766 1/20 0.47
HTT P42858 2/20 0.46
HSD17B10 Q99714 1/20 0.46
TGM2 P21980 1/20 0.46
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
HBB P68871 1/20 0.45
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30817652 0.79 ALDH1A1 (0.73) ALDH1A1NPSR1GAAKDM4ESMN1; SMN2
SCHEMBL30817653 0.79 ALDH1A1 (0.73) ALDH1A1NPSR1GAAKDM4ESMN1; SMN2
SCHEMBL7479419 0.79 ALDH1A1 (0.73) ALDH1A1NPSR1GAAKDM4ESMN1; SMN2
SCHEMBL7672585 0.77 APP (0.52) ALDH1A1GAAKDM4ESMN1; SMN2MEN1
SCHEMBL7672581 0.77 APP (0.52) ALDH1A1GAAKDM4ESMN1; SMN2MEN1
SCHEMBL27806509 0.76 CES1 (0.54) ALDH1A1CES1NPSR1GAABCHE
SCHEMBL2348974 0.75 CES1 (0.73) ALDH1A1CES1NPSR1GAABCHE
SCHEMBL5707675 0.75 MEN1 (0.48) ALDH1A1CES1NPSR1GAABCHE
SCHEMBL22394384 0.73 CES1 (0.51) ALDH1A1CES1NPSR1GAABCHE
SCHEMBL28199867 0.73 HSD17B10 (0.56) ALDH1A1CES1NPSR1GAABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684105-A N-phenyl isatin-mediated ketone-carboxylic acid conversion reaction method 贵州医科大学 2025-03-25 CN disclosed
US-9598441-B2 Therapeutic compounds and methods WAYNE STATE UNIVERSITY (US) 2017-03-21 US disclosed
US-20140221412-A1 THERAPEUTIC COMPOUNDS AND METHODS WAYNE STATE UNIVERSITY (US) 2014-08-07 US disclosed
EP-2750508-A1 THERAPEUTIC COMPOUNDS AND METHODS Wayne State University (US) 2014-07-09 EP disclosed
WO-2013033392-A1 THERAPEUTIC COMPOUNDS AND METHODS WAYNE STATE UNIVERSITY (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221412-A1 THERAPEUTIC COMPOUNDS AND METHODS XPOT, FANCI, XPO5 ALDH1A1 196/4885CES1 655/4885NPSR1 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.